

CITATION REPORT

List of articles citing

Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes

DOI: 10.1016/j.medj.2021.01.005
Med, 2021, 2, 313-320.e4.

Source: <https://exaly.com/paper-pdf/79699291/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
52	Previous SARS-CoV-2 infection increases B.1.1.7 cross-neutralization by vaccinated individuals.		1
51	SARS-CoV-2 Ig G among Healthcare Workers and the General Population. <i>Pathogens</i> , 2021 , 10,	4.5	1
50	Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. <i>Cell Host and Microbe</i> , 2021 , 29, 516-521.e3	23.4	120
49	Personalized Approach to Patient with MRI Brain Changes after SARS-CoV-2 Infection. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	1
48	Population (Antibody) Testing for COVID-19-Technical Challenges, Application and Relevance, an English Perspective. <i>Vaccines</i> , 2021 , 9,	5.3	3
47	Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. <i>Cell Reports Medicine</i> , 2021 , 2, 100290	18	68
46	Highly functional Cellular Immunity in SARS-CoV-2 Non-Seroconvertors is associated with immune protection.		0
45	Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021 , 27, 1205-1211	50.5	1137
44	Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals. <i>Viruses</i> , 2021 , 13,	6.2	6
43	Alterations in T and B cell function persist in convalescent COVID-19 patients. <i>Med</i> , 2021 , 2, 720-735.e4	31.7	22
42	Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19. <i>BMC Medicine</i> , 2021 , 19, 155	11.4	14
41	Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab329	1	2
40	Longitudinal changes in IgG levels among COVID-19 recovered patients: A prospective cohort study. <i>PLoS ONE</i> , 2021 , 16, e0251159	3.7	1
39	Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2. <i>ImmunoHorizons</i> , 2021 , 5, 466-476	2.7	6
38	COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. <i>Nature Communications</i> , 2021 , 12, 3991	17.4	110
37	Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in Adults. <i>Biomedicines</i> , 2021 , 9,	4.8	1
36	Persistence of neutralizing antibodies a year after SARS-CoV-2 infection.		3

35	Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses. <i>Nature Communications</i> , 2021 , 12, 4740	17.4	31
34	Clinical course impacts early kinetics and long-term magnitude and amplitude of SARS-CoV-2 neutralizing antibodies beyond one year after infection.		0
33	Recovery of Memory B-cell Subsets and Persistence of Antibodies in Convalescent COVID-19 Patients. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021 ,	3.2	1
32	Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans. <i>European Journal of Immunology</i> , 2021 ,	6.1	22
31	Immunity to SARS-CoV-2 up to 15 months after infection.		3
30	SARS-CoV-2 Serology Testing in an Asymptomatic, At-Risk Population: Methods, Results, Pitfalls. <i>Infectious Disease Reports</i> , 2021 , 13, 910-916	0.6	0
29	Antibody Dynamics and Durability in Coronavirus Disease-19.. <i>Clinics in Laboratory Medicine</i> , 2022 , 42, 85-96	2.1	1
28	Preclinical efficacy, safety, and immunogenicity of PHH-1V, a second-generation COVID-19 vaccine candidate based on a novel recombinant RBD fusion heterodimer of SARS-CoV-2.		1
27	Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities. <i>Frontiers in Microbiology</i> , 2021 , 12, 789374	5.7	0
26	Persistence of Neutralizing Antibodies to SARS-CoV-2 in First Wave Infected Individuals at Ten Months Post-Infection: The UnIRSA Cohort Study. <i>Viruses</i> , 2021 , 13,	6.2	1
25	Serum from COVID-19 patients early in the pandemic shows limited evidence of cross-neutralization against variants of concern. 2021 ,		
24	Case Report: First Confirmed Case of Coinfection of SARS-CoV-2 With. <i>Frontiers in Tropical Diseases</i> , 2021 , 2, 769330		
23	Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection.. <i>BMC Medicine</i> , 2022 , 20, 26	11.4	21
22	Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants.. <i>Emerging Microbes and Infections</i> , 2021 , 1-45	18.9	0
21	Clinical course impacts early kinetics, magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection.. <i>Cell Reports Medicine</i> , 2022 , 3, 100523	18	1
20	Immunity to SARS-CoV-2 up to 15 months after infection.. <i>iScience</i> , 2022 , 25, 103743	6.1	15
19	Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections.. <i>Frontiers in Immunology</i> , 2022 , 13, 773652	8.4	2
18	Serum from COVID-19 patients early in the pandemic shows limited evidence of cross-neutralization against variants of concern.. <i>Scientific Reports</i> , 2022 , 12, 3954	4.9	0

17	Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up.. <i>Frontiers in Public Health</i> , 2021 , 9, 801609	6	1
16	Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. <i>PLoS Medicine</i> , 2021 , 18, e1003868	11.6	2
15	Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.. <i>Frontiers in Immunology</i> , 2021 , 12, 793191	8.4	3
14	Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors. <i>Frontiers in Immunology</i> , 2022 , 13,	8.4	0
13	A Prospective Study of the Serological, Clinical, and Epidemiological Features of a SARS-CoV-2 Positive Pediatric Cohort. <i>Children</i> , 2022 , 9, 665	2.8	
12	Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals.. <i>Frontiers in Immunology</i> , 2022 , 13, 860215	8.4	0
11	Neutralizing activity to SARS-CoV-2 in 1.2 to 10.0 month convalescent plasma samples of COVID-19: a transversal surrogate in vitro study performed in Quito-Ecuador.. <i>Journal of Medical Virology</i> , 2022 ,	19.7	
10	Vaccine coverage associated with ending a SARS-CoV-2 wave: a retrospective longitudinal analysis.. <i>Clinical Infectious Diseases</i> ,	11.6	
9	Persistent Maintenance of Intermediate Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response. <i>Journal of Virology</i> ,	6.6	0
8	Kinetics of severe acute respiratory syndrome coronavirus 2 infection antibody responses. 13,		0
7	Kinetics of neutralizing antibodies against SARS-CoV-2 infection according to sex, age, and disease severity. 2022 , 12,		1
6	Limited humoral and specific T-cell responses after SARS-CoV-2 vaccination in PLWH with poor immune reconstitution.		2
5	Antibody Response to ChAdOx1 nCoV-19 (AZD1222) Vaccine in Kidney Transplant Recipients. 2022 , 10, 1693		0
4	Preclinical efficacy, safety, and immunogenicity of PHH-1V, a second-generation COVID-19 vaccine, in non-human primates.		0
3	SARS-CoV-2 Antibody response to the Sputnik Vaccine in previous infected Patients and non-infected one.		0
2	RBD-Based ELISA and Luminex Predict Anti-SARS-CoV-2 Surrogate-Neutralizing Activity in Two Longitudinal Cohorts of German and Spanish Health Care Workers.		0
1	Neutralizing Antibodies as Predictors of Vaccine Breakthrough Infection in Healthcare Workers Vaccinated with or without a Heterologous Booster Dose: A Cohort Study during the Third COVID-19 Wave in Peru. 2023 , 11, 447		0